A Phase 1, Open-Label, Dose Finding Study of CC-95251 Alone and in Combination with Antineoplastic Agents in Subjects with Acute Myeloid Leukemia and Myelodysplastic Syndromes

  • Shortt, Jake (Primary Chief Investigator (PCI))
  • Zargari, Ahmad (Chief Investigator (CI))

Project: Research

Project Details

StatusActive
Effective start/end date26/04/22 → 25/04/27

Keywords

  • phase 1 study
  • dose finding
  • treatment efficacy
  • treatment safety
  • leukemia
  • Myelodysplastic Syndromes

Clinical Trial Phase

  • Phase I